Abstract
Sanjad-Sakati syndrome (SSS), also known as hypoparathyroidism-retardation-dysmorphism (HRD) syndrome, is a very rare genetic disorder with an autosomal recessive mode of inheritance, mostly seen in children of Middle Eastern origin. Hypoparathyroidism remains the most characteristic endocrinological feature of SSS; but not the only one. This review outlines and elucidates other endocrinological manifestations that may be seen with this syndrome.
Highlights
BackgroundFirst reported in Saudi Arabia by Sanjad et al in 1988 [1], Sanjad-Sakati syndrome (SSS), known as Richardson-Kirk syndrome, has been listed in Online Mendelian Inheritance of Men (OMIM) no. 241410 as hypoparathyroidism-retardation-dysmorphism (HRD) syndrome
This study aims to explore other endocrinological manifestations that may be seen in this condition as reported in the past, such as hypothyroidism and growth hormone deficiencies
A combination of defects affecting growth hormone (GH), insulin-like growth factor 1 levels (IGF-1) and thyroid hormone secretion coupled with malnutrition caused due to recurrent infections and growth plate defects, may all play the role in the development of short stature in these patients and perhaps, may impede the brain development for which normal thyroid function is so necessary especially during the first year of life [13]
Summary
First reported in Saudi Arabia by Sanjad et al in 1988 [1], Sanjad-Sakati syndrome (SSS), known as Richardson-Kirk syndrome, has been listed in Online Mendelian Inheritance of Men (OMIM) no. 241410 as hypoparathyroidism-retardation-dysmorphism (HRD) syndrome. A combination of defects affecting GH, IGF-1 and thyroid hormone secretion coupled with malnutrition caused due to recurrent infections and growth plate defects, may all play the role in the development of short stature in these patients and perhaps, may impede the brain development for which normal thyroid function is so necessary especially during the first year of life [13]. Since hypoparathyroidism is an almost universal complaint in such patients, the primary management includes treating that defect If such patient presents with symptoms of acute hypocalcemia, the treatment involves intravenous (IV) bolus of 9-15 mg elemental calcium/kg (1 g calcium gluconate = 90 mg elemental calcium), administered over 10-30 mins [19]. SSS is a chronic, progressive disease, for which palliation is the mainstay for management, but recurrent infections limit the lifespan of most patients to below 18 years of age [10]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.